 Hi, how are you doing today? I'm your host Rich and we have a Rich TV live with my very special guest, the CEO of Cognitivity Neurosciences Limited, Sina Habibi. How are you doing today? I'm very good. How are you? I'm doing really, really well. Pleasure to have you on the show. Now, Sina, tell us about yourself and how you got involved with Cognitivity Neurosciences Limited. Sure. So the company started from Cambridge University. We always say the real one in the UK. It was a piece of research with my co-founder whereby he was using latest neuroscience, latest imaging tools available to us, what we call functional MRIs and that's an MRI machine whereby you can look at the function of the brain and find out what's going on in the brain, what parts of the brain activated during a specific task. He was looking at human vision and the idea was to see again when human brain looks around, when we look around ourselves, when our eyes capture images like a camera does, how our brain decodes that information into what it understands and responds to it. There we realize that brain ability to do this, to break down information, visual information and understand what insights them reduces in time. As people get older, it takes them longer to understand what happens around them and respond to it. One example we use is that elderly have to renew their driving license. This is not because they have a condition, but this is because they become slower in responding to things happening around them. Using that specific brain function, we set up a test, a very backup envelope, Matlab code and we took a test from our friends in the uni and we showed a beautiful correlation with age. We showed from 18 to 35, we didn't have any old people around, but when people get older, their performance in our test reduces or declines. This was the beginning of the journey seven years ago. Wow, that's impressive. I love what you guys are doing. Can you tell us what the main focus for cognitive neuroscience is limited is for 2021? Sure. As I said, it took us, this is when you have a medical product, when you have a clinical product, you are dealing with the most risk averse people in the world in physicians and doctors, so you have to bring a lot of evidence to show that your product actually does what you claim it does. That's what we've been doing over the last few years. We validated our claims about this product. Today we have a CE mark product which unlocks all European markets and we have plans in order to receive our FDA approval towards the end of this year. We are going to develop, we have already a product in commercial use within the national health services in the UK. We're going to expand that market and then in the meantime, we're having discussions with different clinicians, hospital groups in the US to start using the product free of charge basis because we don't have FDA yet. We cannot sell anything in the US, but we want to get that user data in the US how clinicians go about using our technology so that we fine tune our product or as and when the FDA approval comes in, you're ready to go out and scale up our operations in the US. That's fantastic. Now, Cognitivity Neuroscience has limited recently announced it has reached an agreement with Dutch telehealth company Lucy HealthTech regarding the deployment of Cognitivity's wellness app. Big news. Can you tell us what type of potential revenues this could generate for the company once the app is fully up and running? Great question. I can't even put a number on it because it's so big that it's hard to put the number on it, but just to give you an idea, any corporation, not any corporation, any SME, any small and medium enterprises, anywhere you want to assess the well-being of your staff, you can use our products and well-being, improving well-being of your staff directly correlates to their performance and their productivity. So in that press release we mentioned a Deloitte report whereby it's shown that companies, corporations average spend around $800 a year on corporate well-being without any tool to show whether these products, these programs working or not. And also as we speak there's a huge debate across the world of CEOs. Some say we all have to work remotely. Some bonds such as Goldman Sachs CEO that wants all the staff back in the office because they believe, based on their opinion, nothing more than that, that one way or the other is the right way. But now we have a tool for the first time that can tell people which model works for your staff, for your company. So this is a site anywhere, any corporation in North America, in Asia will be able to have a very specific and sensitive measurement of well-being of their staff. And that's the size of the market that we have. And pretty much no competition. There's no other product that can do this. Other cognitive tests are long, they're bulky and people get to learn them so they become better at them. One of the key benefits of our test is that we've shown the test is not learnable. So if you give it to your staff and take the test every day, they don't become better at the test because they've taken it over time. But if their lifestyle improves or if they work from home and that has a positive impact on their brain health, then you can see that on their test result. Wow. I love technology. Just changing and moving so fast. It's mind boggling what you guys are doing here, but it's amazing when you think about the future of technology and what you're capable of. It's pretty exciting what you guys are doing. Can you give us a run down of the team? We love here at Rich TV Live to learn about the team and management. Can you give us a run down of the team at Cognitivity Neuroscience is Limited and what each member brings to the team? Absolutely. We have a little bit of a bias in Cambridge alumni for a capital in the company because of the roots of the company because it all started. We always said that Cambridge Pops are the best recruitment centers because all you have to do is to go there, get a pint of beer in your hand and say it's impossible to solve this problem. And then two people say no, it's not. And then you say, okay, you guys are recruited. So we have a lot of people coming from Cambridge. The most notable one is my co-founder who is one of the, I used to say rising stars in neuroscience, but he is a shining star in neuroscience. He's been conducting research at Cambridge University and also the second Cambridge in the US with MIT and Party at Harvard. He is a neuroscientist with a lot of publication, particularly in human vision and brain mapping. Our chief compliance officer, Mark Phillips, was a veteran of pharmaceutical industry. He was at GSK for 35 years and his role was precisely in taking R&D projects from when they are validated to the point that they are regulated and ready to be launched. Another very important team member is Dr. Thomas Sawyer, where I met at George Business School, which is our business school at Cambridge, and he was doing his executive MBA after having 10, 15 years of work in the world of ventures and private equity and venture capital. And he was mentoring different startups. And he always tells me that the moment we pitched, he said that this is the company to work for and be involved with. And also we have Dr. Chris Calafatis, who is an old age psychiatrist. In the team, he was one of the youngest old age psychiatrists in London. And when we wrote the first code, we made it look like a game and we started to collect data. That was how we trained our AI. When we gave it to him, it was one of these pop discussions, actually. We realized that over the weekend, he's taken the test 250 times and we knew at the time that we've got someone who's got a lot of interest in what we're doing. So we went back and we started working with him since the very, very early days of the company. Sina, what separates you guys from your competition? You mentioned there's no competition. Is there really no competition at all? Every problem, I always say, in my old days, I was teaching entrepreneurship in Cambridge. And I always say, every problem is getting solved somehow. And is it efficiently solved? I'm not so sure. And that's exactly with this case. There are solutions, but they're all approaches to the problem. We often say the methodology to detect cognitive impairment has not changed since the very beginning of discovering these diseases. There are memory questions asked then. We're still asking memory questions. But what we do, we have, coming back to what we said, what I mentioned earlier, using latest neuroscience. Our understanding of the brain over the last five years is more than what we knew for the entire history. And this is because of the breakthroughs in our imaging, our computational power. And that's what has given us the knowledge of the brain that it was not existing before. And add to that is our artificial intelligence components. We have a very powerful data component in our technology. We have a patented technology in our cognitive assessment. That's one part. But we've been training an AI model, which keeps getting trained as we collect more data. The analogy we use is that we've had a neurologist that has been seeing patients and not forgetting any of them since day one that we started collecting these data seven years ago. As we collect more data, it becomes more and more sensitive and specific. So to answer the question, two folds, our competitions normally, we haven't seen anyone using the AI to the extent that we do. And also latest neuroscience. We are not going through those old approaches of asking memory questions. Who was the president of the United States? Who got assassinated in 60s? That's not what we do. That's very late stage. It's good to capture the disease when it's really developed. And it's late stage. We pick it up subtle and subclinical before anybody else can pick it up. That's great. Love what you guys are doing. I love disruptive technologies. And we love here at Rich TD Live tight share structures. We're a group of investors from all over the world. We love tight share structures. Can you explain your share structure and how much is held by insiders and potentially institutions? We have close to 75% of the company owned by the insiders. We haven't had any institutional investor. It's been all through retail over the last few years. But that's what we're going to change in the next few months, probably. Very good. Very good. I like that. And do you know what your issue of standing is off by heart? Do you have an estimate of your issue of standing share structure? Not really exactly at the moment. Okay. We'll get into that in the future. Does cognitive neuroscience is limited have any plans of raising funds in the near future? And if so, what would those funds be used for? We don't have any immediate plan. Having said that, we look at any offer on the table and assess it, particularly coming to strategic investors, whether it's a venture arm of big pharma or big medical devices or even software, because we sit in a very, interesting interface of pharma, software, medical devices. So there's a lot of interesting synergy for investments from these big players. And if we do that, that is going to be in order to accelerate growth significantly. We have enough capital to reach our milestones with no problem. But with a strategic investor, this could be accelerated significantly. Fantastic. If there was one thing that you would want shareholders to know about cognitively neurosciences, what would it be? The problem that we're solving is such a big problem and such a huge problem that can be, I can use some interesting analogy to it. It's similar to assessing one's blood pressure or someone's eyesight. You all have experience of being, checking your eyesight with moving your hand to the left or right or up or down. That simple but sensitive and accurate test solves a huge problem. And that's where we stand with the brain. We have a very sensitive but simple test, which is hugely scalable. And I want you to think about anywhere that you need to assess brain in a very short, sensitive and accurate way, you will need to use our technology. And there's no other tool that does this. It is level of efficiency. Wow, that's incredible. We've got investors to tell you how huge the size of the problem that we're solving is and how significant our solution is. We've got investors all over the world that are going to watch this video and they're going to potentially be interested in contacting you. What's the best way for them to reach you? The most direct way is invest at cognitively.com. It's our email address and we review this. We review incoming emails, but we have social media footprint. You can find us on any of the social media channels. And yeah, we are actively listening to our investors, to our customers, because that's how you build a great company and how you build a great product. So excited to learn more and watch your company evolve and grow. Love what you guys are doing. Thank you for joining us, the CEO of Cognitivity Neurosciences Limited, Sina Habibi. And if you guys like this video, please smash the like button, comment down below, share the video everywhere and subscribe. Hit the bell for notifications so every time we have any other breaking news or anything happening, you'll get access to it first. And once again, the CEO of Cognitivity Neurosciences, Sina Habibi. Nice enough to join us. Remember guys, Rich TV Live is strictly for education, entertainment purposes. Always do your due diligence. Always do your research before you invest in anything that we talk about. Consult a financial advisor. Chances are when you consult a financial advisor, they're going to say, where'd you get this pick? And then you're going to say from Rich TV Live and they're going to say it's a great pick. I really like the pick. Sina, keep up the great work. Love what you guys are doing. We love disruptive companies. And I think you guys are going to go really far. And congratulations on our success so far. Thank you so much. Thanks for having me. Always a pleasure. Thank you for joining us. Thank you. Thank you guys for watching. Have a nice day, everybody.